hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 23:11:04 - browse：7

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： A new study sees potential in DNA sequencing of infants

WSS

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

What to know about OceanGate, the company behind the missing Titanic submersible

Leqembi, other new Alzheimer’s drugs require better biomarkers

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Bring on the sabbaticals for nurses

leisure time

hotspot

hotspot

Activists slam private health insurers over coverage restrictions

Adam's Take: Intra

The cancer drug shortage isn’t new — and neither are the solutions

Biotech investment managers search for lucrative opportunities

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Mirador, a new biotech startup, launches with $400 million

23andMe had bad news about my health. I wish a person had delivered it

CRISPR technology availability, affordability needs to be expanded

New air purifier tech could be key to improving indoor air quality

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

leisure time

Biotech investment managers search for lucrative opportunities

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Readout Newsletter: Illumina, CRISPR, Regeneron

Steward Health Care expansion into Malta flopped

N.Y. state detects polio case, first in the U.S. since 2013

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

hotspot

hotspot

Wikipedia